CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology

[ad_1] SINGAPORE, Dec. 5, 2023 /PRNewswire/ — CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based…

CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update

[ad_1] Conference call webcast is scheduled for November 22 at 9 a.m. ET. SINGAPORE, Nov. 17, 2023 /PRNewswire/ — CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company…

Chinese Patent Granted for CytoMed Therapeutics’ Licensed iPSC-Based Technology

[ad_1] SINGAPORE, Sept. 25, 2023 /PRNewswire/ — CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic…